Intra-gastrointestinal Monitoring Device (PressureDOT®) and Centurion IAP Monitoring Device Comparison Study: Pivotal Study of Safety and Performance.

Exclusion Criteria

• •1. The patient is anticipated to undergo an MRI examination within seven days after ingestion of the capsule.
• •2. The patient is anticipated to undergo radiotherapy within seven days after ingestion of the capsule.
• •3. Patients who are on ECMO treatment.
• •4. Conscious patients with a history of difficulty with swallowing due to functional or anatomic disorder.
• •5. Patients with a history of bowel stenosis.
• •6. Patients with a history of bowel mechanical obstruction.
• •7. Patients with a past history of intestinal diverticula, intestinal obstruction/stenosis, intestinal reconstructed operation or any past history indicating a high risk for capsule retention based on the PI's evaluation and judgement.
• •8. Patients with obvious clinical evidence of gastrointestinal tract obstruction or severe paralytic ileus that need immediate surgical intervention.
• •9. Female subjects who are pregnant, planning on becoming pregnant or nursing. To exclude the possibility of pregnancy risk in the enrollment stage, a pregnancy test will be prescribed to the female subjects who fits the fertility status.
• •10. The presence of any other active implanted device, such as a cardiac pacemaker or other implanted electromedical devices.
• •11. The presence of any other wireless sensor or transmitter located in the abdomen (excluding compatible devices also in use for pressure sensing within the body).
• •12. Patients with Crohn's disease or diverticulitis.
• •13. Patients diagnosed with radiation enteritis.
• •14. Patients with severe systemic diseases and not allowed to join this study by the principal investor's judgement, such as severe congestive heart failure, renal failure or liver diseases.
• •15. Congenital anomalies of gastrointestinal tract or any other anatomical abnormality of the head, neck, chest, or abdomen that would be a contraindication to placement of the PressureDOT® device and usage of the external device.
• •16. Has a BMI \> 35 kg/m² or \<18.5 kg/m²
• •17. Subjects with any contraindication to urinary bladder catheterization or intravesical intra-abdominal pressure measurement, including but not limit:
• •1. Known or suspected urethral injury, severe urethral stricture or recent pelvic or lower urinary tract trauma.
• •2. Recent urological surgery involving the bladder, prostate, or urethra that precludes safe Foley catheter placement.
• •3. Clinically diagnosed urosepsis or active, symptomatic urinary tract infection.
• •4. Neurogenic bladder with documented poor bladder compliance, in the judgment of the Principal Investigator.
• •5. Confirmed anuria or urinary obstruction that may compromise the accuracy or safety of intravesical pressure measurement.
• •6. Gross hematuria or bladder outlet obstruction that contraindicates Foley catheterization.
• •18. A patient who, in the judgment of the Principal Investigator, is not appropriate for enrollment.
• •19. A patient or his/her legal representative/surrogate who isn't fluent in English.
• •20. A patient or his/her legal representative/surrogate who doesn't sign the Informed Consent.